Specialty resin leadership CBL Biopharma has a long-standing reputation in the peptide industry, including developing and commercialising trityl resins and 2-chlorotrityl chloride resin, suggesting a strong opportunity to upsell advanced starting materials and resin technologies to peptide developers and manufacturers.

GMP manufacturing footprint With GMP production for peptide clinical and commercial material across all development stages and multiple clean rooms, there is potential to partner on scale-up programs, contract manufacturing, and ongoing supply for peptide APIs and intermediates.

Global logistics presence A Boulder, Colorado office and warehouse extend US market access, presenting a gateway for US-based pharmas and contract organizations to streamline procurement of peptide materials, intermediates, and API components.

Intellectual property engine CBL’s portfolio includes novel solid phase resins and protected Fmoc amino acids, along with IP around insulin-like peptides and longer peptides, offering collaboration or licensing opportunities for unique materials and manufacturing methodologies.

SME with growth potential Operating with 11-50 employees and revenue in the one-digit millions, CBL represents a strategic target for partnerships, OEM supply agreements, and co-development deals with larger CDMOs or peptide-focused clients seeking specialized materials and flexible production capacity.